Table 1. Characteristics of patients before and after intervention.
| Variable | Before, n = 71 | After, n = 148 | P |
| Age, mean years±SD (range) | 62.0±10.6 (40–82) | 59.0±17.0 (17–87) | 0.86 |
| Male sex | 58 (81.7) | 95 (64.2) | <0.05 |
| Malignant disease | |||
| Leukemia | 27 (38.0) | 78 (52.7) | <0.05 |
| Lymphoma | 20 (28.2) | 46 (31.1) | 0.75 |
| MDS | 7 (9.9) | 9 (6.1) | 0.40 |
| Multiple myeloma | 17 (23.9) | 7 (4.7) | <0.01 |
| Other | 0 (0.0) | 8 (5.4) | 0.06 |
| Therapy for hematological disorders | |||
| Chemotherapy | 61 (85.9) | 136 (91.9) | 0.23 |
| Autologous HSCT | 9 (12.7) | 8 (5.4) | 0.10 |
| Therapy for infectious diseases | |||
| Use of G-CSF | 41 (57.7) | 71 (48.0) | 0.20 |
| Use of Antimycotic drugs | 54 (76.1) | 84 (56.8) | <0.01 |
| Intravenous hyperalimentation catheter | 49 (69.0) | 115 (77.7) | 0.19 |
| Neutrophil cell count (/uL), mean | 299.5±326.0 (0–968) | 155.7±258.2(0–1270) | <0.05 |
| number ± SD (range) | |||
| MASCC score ± SD (range) | 21.3±1.8 (16–24) | 21.4±1.4 (17–23) | 0.94 |
P-value shows statistical comparison for each variable between patients receiving pre-intervention and those receiving intervention.
MDS, myelodysplastic syndromes;HSCT, hematopoietic stem cell transplantation.
G-CSF, granulocyte colony-stimulating factor; MASCC, multinational association for supportive care in cancer.